Scalper1 News
The Food and Drug Administration approved Bristol-Myers Squibb’s (BMY) PD-1 inhibitor Opdivo for squamous-cell lung cancer Wednesday, well ahead of the expected timeline. The stock jumped to a 14-year high near 65. Opdivo was first approved for advanced melanoma in December, and positive lung-cancer data in January increased Wall Street’s confidence that it would also get approved for that disease. However, they weren’t all prepared for it to Scalper1 News
Scalper1 News